Regulation of plasminogen activators in human thyroid follicular cells and their relationship to differentiated function

Journal of Cellular Physiology

Volumn 212, Issue 3, 2007, Pages 643-654

  Susarla, Radhika ^a   Watkinson, John C ^a   Eggo, Margaret C ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; APROTININ; BISINDOLYLMALEIMIDE; CYCLIC AMP; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; INSULIN; IODINE 125; LY 379196; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PLASMINOGEN ACTIVATOR; PROTEIN KINASE C; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; THYROTROPIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; AUTOCRINE EFFECT; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID FOLLICLE CELL;

ADENYLATE CYCLASE; APROTININ; CELL DIFFERENTIATION; CELLS, CULTURED; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTORS; FLAVONOIDS; FORSKOLIN; HUMANS; INDOLES; INSULIN; IODINE; IODINE RADIOISOTOPES; MALEIMIDES; MESYLATES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PLASMINOGEN INACTIVATORS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRROLES; RNA, MESSENGER; SERINE PROTEINASE INHIBITORS; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; THYROID GLAND; THYROTROPIN; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 34547936178     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcp.21060     Document Type: Article

References (48)

1. Aguirre-Ghiso JA, Liu D, Mignatti A, Kovalski K, Ossowski L. 2001. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12:863-879.
2. Akkawi S, Nassar T, Tarshis M, Cines DB, Higazi AA. 2006. LRP and {alpha}vbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol 291:H1351-1359.
3. Ambesi-Impiombato FS, Parks LA, Coon HG. 1980. Culture of hormone-dependent functional epithelial cells from rat thyroids. Proc Natl Acad Sci USA 77:3455-3459.
4. Blasi F. 1996. The urokinase receptor and cell migration. Semin Thromb Hemost 22:513-516.
5. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, Marchesi F, Allavena P, Greco A, Collini P, Pilotti S, Cassinelli G, Bressan P, Fugazzola L, Mantovani A, Pierotti MA. 2005. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825-14830.
6. Bramley MD, Harrison BJ. 1996. Papillary microcarcinoma of the thyroid gland. Br J Surg 83:1674-1683.
7. Canipari R, O'Connell ML, Meyer G, Strickland S. 1987. Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissue-type plasminogen activator. J Cell Biol 105:977-981.
8. Cocks HC, Thompson S, Turner FE, Logan A, Franklyn JA, Watkinson JC, Eggo MC. 2003. Role and regulation of the fibroblast growth factor axis in human thyroid follicular cells. Am J Physiol Endocrinol Metab 285:E460-469.
9. Davies EL, Ramsden JD, Cocks H, Searle PF, Watkinson JC, Ueno H, Logan A, Franklyn JA, Mautner V, Eggo MC. 2003. Adenovirus-mediated expression of dominant negative fibroblast growth factor (FGF) receptor 1 in thyroid cells blocks FGF effects and reduces goitrogenesis in mice. J Clin Endocrinol Metab 88:4472-4480.
10. Eggo MC, Bachrach LK, Burrow GN. 1990. Interaction of TSH, insulin and insulin-like growth factors in regulating thyroid growth and function. Growth Factors 2:99-109.
11. Eggo MC, Sheppard MC, Evans FJ, Lord JM. 1994. Phorbol esters showing selective activation of PKC isozymes in vitro regulate thyroid function and insulin-like growth factor binding protein secretion. Cell Signal 6:439-448.
12. Eggo MC, Hopkins JM, Franklyn JA, Johnson GD, Sanders DS, Sheppard MC. 1995. Expression of fibroblast growth factors in thyroid cancer. J Clin Endocrinol Metab 80:1006-1011.
13. Eggo MC, King WJ, Black EG, Sheppard MC. 1996. Functional human thyroid cells and their insulin-like growth factor-binding proteins: regulation by thyrotropin, cyclic 3′,5′ adenosine monophosphate, and growth factors. J Clin Endocrinol Metab 81:3056-3062.
14. Eggo MC, Quiney VM, Campbell S. 2003. Local factors regulating growth and function of human thyroid cells in vitro and in vivo. Mol Cell Endocrinol 213:47-58.
15. Erem C, Ersoz HO, Karti SS, Ukinc K, Hacihasanoglu A, Deger O, Telatar M. 2002. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest 25:345-350.
16. Flynn RW, Macdonald TM, Jung RT, Morris AD, Leese GP. 2006. Mortality and vascular outcomes in patients treated for thyroid dysfunction. J Clin Endocrinol Metab 91:2159-2164.
17. Hamilton JA, Cheung D, Filonzi EL, Piccoli DS, Wojta J, Gallichio M, McGrath K, Last K. 1992. Independent regulation of plasminogen activator inhibitor 2 and plasminogen activator inhibitor 1 in human synovial fibroblasts. Arthritis Rheum 35:1526-1534.
18. Holmberg M, Leonardsson G, Ny T. 1995. The species-specific differences in the cAMP regulation of the tissue-type plasminogen activator gene between rat, mouse and human is caused by a one-nucleotide substitution in the cAMP-responsive element of the promoters. Eur J Biochem 231:466-474.
19. Kheradmand F, Werb Z. 2002. Shedding light on sheddases: role in growth and development. Bioessays 24:8-12.
20. Ma Z, Webb DJ, Jo M, Gonias SL. 2001. Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci 114:3387-3396.
21. Mak WW, Eggo MC, Burrow GN. 1984. Thyrotropin regulation of plasminogen activator activity in primary cultures of ovine thyroid cells. Biochem Biophys Res Commun 123:633-640.
22. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, Marme D, Schachtele C. 1993. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J Biol Chem 268:9194-9197.
23. McCabe NP, Angwafo FF3rd, Zaher A, Selman SH, Kouinche A, Jankun J. 2000. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep 7:879-882.
24. Medcalf RL, Schleuning WD. 1991. Regulation of human tissue-type plasminogen activator gene transcription by epidermal growth factor and 3′,5′-cyclic adenosine monophosphate. Mol Endocrinol 5:1773-1779.
25. Montuori N, Salzano S, Rossi G, Ragno P. 2000. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor. FEBS Lett 476:166-170.
26. Nasir A, Chaudhry AZ, Gillespie J, Kaiser HE. 2000. Papillary microcarcinoma of the thyroid: a clinico-pathologic and prognostic review. In Vivo 14:367-376.
27. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 13:9-22.
28. Parfyonova YV, Plekhanova OS, Tkachuk VA. 2002. Plasminogen activators in vascular remodeling and angiogenesis. Biochemistry (Mosc) 67:119-134.
29. Patel VA, Logan A, Watkinson JC, Uz-Zaman S, Sheppard MC, Ramsden JD, Eggo MC. 2003. Isolation and characterization of human thyroid endothelial cells. Am J Physiol Endocrinol Metab 284:E168-E176.
30. Patel NG, Kumar S, Eggo MC. 2005. Essential role of fibroblast growth factor signaling in preadipoctye differentiation. J Clin Endocrinol Metab 90:1226-1232.
31. Plouet J, Moro F, Bertagnolli S, Coldeboeuf N, Mazarguil H, Clamens S, Bayard F. 1997. Extracellular cleavage of the vascular endothelial growth factor 189-amino acid form by urokinase is required for its mitogenic effect. J Biol Chem 272:13390-13396.
32. Ploug M, Behrendt N, Lober D, Dano K. 1991. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost 17:183-193.
33. Presta M, Maier JA, Ragnotti G. 1989. The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediatedthrough protein kinase C in fetal bovine aortic endothelial cells. J Cell Biol 109:1877-1884.
34. Ragno P, Montuori N, Salzano S, Rossi G. 1999. Urokinase-type plasminogen-activator and normal thyroid cell adhesion to the extracellular matrix. Biochimie 81:355-358.
35. Ramsden JD, Yarram S, Mathews E, Watkinson JC, Eggo MC. 2002. Thyroid follicular cells secrete plasminogen activators and can form angiostatin from plasminogen. J Endocrinol 173:475-481.
36. Saksela O. 1985. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 823:35-65.
37. Slosberg ED, Yao Y, Xing F, Ikui A, Jirousek MR, Weinstein IB. 2000. The protein kinase C beta-specific inhibitor LY379196 blocks TPA-induced monocytic differentiation of HL60 cells the protein kinase C beta-specific inhibitor LY379196 blocks TPA-induced monocytic differentiation of HL60 cells. Mol Carcinog 27:166-176.
38. Smith PC, Santibanez JF, Morales JP, Martinez J. 2004. Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin. J Periodontal Res 39:380-387.
39. Stepanova W, Tkachuk VA. 2002. Urokinase as a multidomain protein and polyfunctional cell regulator. Biochemistry (Mosc) 67:109-118.
40. Stump DC, Lijnen HR, Collen D. 1986. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 261:17120-17126.
41. Susarla R, Watkinson JC, Eggo MC. 2005. Functional Significance of expression of the receptors for Vascular endothelial growth factors on thyroid follicular cells. Endocrine Abstracts 15: Abstract no: P152.
42. Thompson SD, Franklyn JA, Watkinson JC, Verhaeg JM, Sheppard MC, Eggo MC. 1998. Fibroblast growth factors 1 and 2 and fibroblast growth factor receptor 1 are elevated in thyroid hyperplasia. J Clin Endocrinol Metab 83:1336-1341.
43. Tolli R, Monaco L, Di Bonito P, Canipari R. 1995. Hormonal regulation of urokinase- and tissue- type plasminogen activator in rat Sertoli cells. Biol Reprod 53:193-200.
44. Tranque P, Robbins R, Naftolin F, Andrade-Gordon P. 1992. Regulation of plasminogen activators and type-1 plasminogen activator inhibitor by cyclic AMP and phorbol ester in rat astrocytes. Glia 6:163-171.
45. Ulisse S, Baldini E, Toller M, Marchioni E, Giacomelli L, De Antoni E, Ferretti E, Marzullo A, Graziano FM, Trimboli P, Biordi L, Curcio F, Gulino A, Ambesi-Impiombato FS, D'Armiento M. 2006. Differential expression of the components of the plasminogen activating system in human thyroid tumour derived cell lines and papillary carcinomas. Eur J Cancer 42:2631-2638.
46. Van Sande J, Dequanter D, Lothaire P, Massart C, Dumont JE, Erneux C. 2006. Thyrotropin stimulates the generation of inositol 1,4,5-trisphosphate in human thyroid cells. J Clin Endocrinol Metab 91:1099-1107.
47. Vassalli JD, Sappino AP, Belin D. 1991. The plasminogen activator/plasmin system. J Clin Invest 88:1067-1072.
48. Zoellner H, Wojta J, Gallicchio M, McGrath K, Hamilton JA 1993. Cytokine regulation of the synthesis of plasminogen activator inhibitor-2 by human vascular endothelial cells. Comparison with plasminogen activator inhibitor-1 synthesis. Thromb Haemost 69:135-140.